NO20012555L - Fremgangsmåte for å fremme cervikale og vaginale sekresjoner - Google Patents

Fremgangsmåte for å fremme cervikale og vaginale sekresjoner

Info

Publication number: NO20012555L
Authority: NO; Norway
Prior art keywords: triphosphate; vaginal secretions; treatment; receptor agonists; purinergic receptor
Prior art date: 1998-11-25

Application number

NO20012555A

Other languages

English (en)

Norwegian (no)

Other versions

NO20012555D0 (no

Inventor

William Pendergast

Sammy R Shaver

David J Drutz

Janet L Rideout

Original Assignee

Inspire Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-25

Filing date

2001-05-23

Publication date

2001-07-24

2001-05-23 Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc

2001-05-23 Publication of NO20012555D0 publication Critical patent/NO20012555D0/no

2001-07-24 Publication of NO20012555L publication Critical patent/NO20012555L/no

Links

210000003756 cervix mucus Anatomy 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
230000001737 promoting effect Effects 0.000 title 1
239000003227 purinergic agonist Substances 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
206010047791 Vulvovaginal dryness Diseases 0.000 abstract 2
230000004936 stimulating effect Effects 0.000 abstract 2
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 abstract 1
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 abstract 1
PCDQPRRSZKQHHS-UHFFFAOYSA-N Cytidine 5'-triphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-UHFFFAOYSA-N 0.000 abstract 1
102100028045 P2Y purinoceptor 2 Human genes 0.000 abstract 1
101710096700 P2Y purinoceptor 2 Proteins 0.000 abstract 1
102100028070 P2Y purinoceptor 4 Human genes 0.000 abstract 1
108050009478 P2Y purinoceptor 4 Proteins 0.000 abstract 1
229920000388 Polyphosphate Polymers 0.000 abstract 1
PGAVKCOVUIYSFO-XVFCMESISA-N UTP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 abstract 1
229960001456 adenosine triphosphate Drugs 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
PCDQPRRSZKQHHS-ZAKLUEHWSA-N cytidine-5'-triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO[P@](O)(=O)O[P@@](O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-ZAKLUEHWSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000009245 menopause Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
-1 nucleotide triphosphates Chemical class 0.000 abstract 1
239000001205 polyphosphate Substances 0.000 abstract 1
235000011176 polyphosphates Nutrition 0.000 abstract 1
239000001226 triphosphate Substances 0.000 abstract 1
235000011178 triphosphate Nutrition 0.000 abstract 1
PGAVKCOVUIYSFO-UHFFFAOYSA-N uridine-triphosphate Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Reproductive Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

NO20012555A 1998-11-25 2001-05-23 Fremgangsmåte for å fremme cervikale og vaginale sekresjoner NO20012555L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/199,912 US6462028B2 (en)	1997-07-25	1998-11-25	Method of promoting cervical and vaginal secretions
PCT/US1999/027634 WO2000030629A2 (en)	1998-11-25	1999-11-19	Method of promoting cervical and vaginal secretions

Publications (2)

Publication Number	Publication Date
NO20012555D0 NO20012555D0 (no)	2001-05-23
NO20012555L true NO20012555L (no)	2001-07-24

Family

ID=22739534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012555A NO20012555L (no)	1998-11-25	2001-05-23	Fremgangsmåte for å fremme cervikale og vaginale sekresjoner

Country Status (12)

Country	Link
US (2)	US6462028B2 (id)
EP (1)	EP1133304A2 (id)
JP (1)	JP2003524609A (id)
KR (1)	KR20010101066A (id)
CN (1)	CN1348378A (id)
AU (1)	AU764452B2 (id)
BR (1)	BR9915636A (id)
CA (1)	CA2352262A1 (id)
ID (1)	ID29801A (id)
NO (1)	NO20012555L (id)
WO (1)	WO2000030629A2 (id)
ZA (1)	ZA200104310B (id)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6319908B1 (en)	1996-07-03	2001-11-20	Inspire Pharmaceuticals, Inc.	Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en)	1996-07-23	2002-05-07	Inspire Pharmaceuticals	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6596725B2 (en)	1997-02-10	2003-07-22	Inspire Pharmaceuticals, Inc.	Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en)	1997-02-10	2007-05-29	Inspire Pharmaceuticals, Inc.	Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en)	1997-02-10	2004-11-16	Inspire Pharmaceuticals, Inc.	Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7078391B2 (en)	1997-02-10	2006-07-18	Inspire Pharmaceuticals, Inc.	Method of treating edematous retinal disorders
TW593331B (en)	1997-07-25	2004-06-21	Inspire Pharmaceuticals Inc	Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6872710B2 (en)	1997-07-25	2005-03-29	Inspire Pharmaceuticals, Inc.	Di(uridine 5′)-tetraphosphate and salts thereof
KR20010013797A (ko)	1997-07-25	2001-02-26	인스파이어 파마슈티컬스 인코퍼레이티드	디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
US6462028B2 (en)	1997-07-25	2002-10-08	Inspire Pharmaceuticals, Inc.	Method of promoting cervical and vaginal secretions
US6555675B2 (en) *	2000-08-21	2003-04-29	Inspire Pharmaceuticals, Inc.	Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7452870B2 (en)	2000-08-21	2008-11-18	Inspire Pharmaceuticals, Inc.	Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en)	2000-08-21	2006-03-28	Inspire Pharmaceuticals, Inc.	Composition and method for inhibiting platelet aggregation
US6867199B2 (en)	2000-08-21	2005-03-15	Inspire Pharmaceuticals, Inc.	Dinucleoside polyphosphate compositions and their therapeutic use
WO2003000056A1 (en)	2001-06-25	2003-01-03	Inspire Pharmaceuticals, Inc.	Joint lubrication with p2y purinergic receptor agonists
KR20050043761A (ko)	2001-11-06	2005-05-11	인스파이어 파마슈티컬스 인코퍼레이티드	염증성 질환의 치료 또는 예방 방법
EP1348466A3 (en) *	2002-02-01	2003-10-29	Inspire Pharmaceuticals, Inc.	Method for treating pain with adenosine-tetraphosphates
US20030162769A1 (en) *	2002-02-26	2003-08-28	Easterling W. Jerry	Composition and method for treating vulvodynia
US20050176782A1 (en) *	2002-02-26	2005-08-11	Easterling W. J.	Medicament and method for treating vulodynia
US7179481B2 (en) *	2002-09-19	2007-02-20	Kimberly-Clark Worldwide, Inc.	Vaginal health products
MXPA05004121A (es) *	2002-10-18	2006-02-17	Molichem Medicines Inc	Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
US7056889B2 (en) *	2002-12-16	2006-06-06	Kimberly-Clark, Worldwide, Inc.	Compounds that bind P2Y2 or P2Y1 receptors
GB0312845D0 (en) *	2003-06-04	2003-07-09	Paradigm Therapeutics Ltd	Use of componds in medicine
CA2565545A1 (en) *	2004-05-06	2005-12-08	Molichem Medicines, Inc.	Treatment of ocular diseases and disorders using lantibiotic compositions
US7326683B2 (en) *	2004-05-06	2008-02-05	Molichem Medicines, Inc.	Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US8147399B2 (en)	2004-05-11	2012-04-03	Gloth David A	Device and method for applying a biocompatible substance to a female stimulation device
US6949067B1 (en) *	2004-05-11	2005-09-27	Dann Jeffrey A	Device and method for enhancing female sexual stimulation
GB0417886D0 (en) *	2004-08-11	2004-09-15	Univ Cardiff	Method and means for enhanced pulmonary delivery
DE102004054552A1 (de)	2004-11-11	2006-05-18	Hcb Happy Child Birth Holding Ag	Neue Zusammensetzung zur Erleichterung der Humangeburt
US7368439B2 (en)	2005-06-15	2008-05-06	Bar - Ilan University	Dinucleoside poly(borano)phosphate derivatives and uses thereof
GB201209244D0 (en) *	2012-05-25	2012-07-04	Globalacorn Ltd	Compositions
EP2906302A1 (en) *	2012-10-12	2015-08-19	Inoflex AB	Composition for alleviating conditions associated with vaginal dryness
GB201320962D0 (en) *	2013-11-27	2014-01-08	Globalacorn Ltd	Compositions
GB201320959D0 (en) *	2013-11-27	2014-01-08	Globalacorn Ltd	Compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3639562A (en)	1970-04-29	1972-02-01	Smith Kline French Lab	Vaginal suppositories and impregnated tampons
US3639561A (en)	1970-04-29	1972-02-01	Smith Kline French Lab	Vaginal suppositories and impregnated tampons
US5482706A (en) *	1992-04-17	1996-01-09	Takeda Chemical Industries, Ltd.	Transmucosal therapeutic composition
JPH05346549A (ja)	1992-04-17	1993-12-27	Canon Inc	走査光学装置
US5635160A (en)	1995-06-07	1997-06-03	The University Of North Carolina At Chapel Hill	Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
IT1277373B1 (it) *	1995-07-28	1997-11-10	Consiglio Nazionale Ricerche	Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
US6423694B1 (en)	1996-02-21	2002-07-23	Inspire Pharmaceuticals, Inc.	Method of treating otitis media with uridine triphosphates and related compounds
US5837861A (en) *	1997-02-10	1998-11-17	Inspire Pharmaceuticals, Inc.	Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
US5900407A (en)	1997-02-06	1999-05-04	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with uridine triphosphates and related compounds
NZ332426A (en)	1996-03-27	2000-09-29	Univ North Carolina	Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US5789391A (en)	1996-07-03	1998-08-04	Inspire Pharmaceuticals, Inc.	Method of treating sinusitis with uridine triphosphates and related compounds
US6319908B1 (en) *	1996-07-03	2001-11-20	Inspire Pharmaceuticals, Inc.	Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en)	1996-07-23	2002-05-07	Inspire Pharmaceuticals	Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
DK0981534T3 (da)	1997-02-06	2006-09-04	Inspire Pharmaceuticals Inc	Dinukleotider og deres anvendelser
US6462028B2 (en)	1997-07-25	2002-10-08	Inspire Pharmaceuticals, Inc.	Method of promoting cervical and vaginal secretions
KR20010013797A (ko) *	1997-07-25	2001-02-26	인스파이어 파마슈티컬스 인코퍼레이티드	디(우리딘 5'-테트라포스페이트) 염 및 그의 제조방법과용도
US6294188B1 (en)	1998-07-09	2001-09-25	Aviana Biopharm Inc.	Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women

1998
- 1998-11-25 US US09/199,912 patent/US6462028B2/en not_active Expired - Lifetime
1999
- 1999-11-19 AU AU17412/00A patent/AU764452B2/en not_active Ceased
- 1999-11-19 KR KR1020017006504A patent/KR20010101066A/ko not_active Withdrawn
- 1999-11-19 CA CA002352262A patent/CA2352262A1/en not_active Abandoned
- 1999-11-19 EP EP99960542A patent/EP1133304A2/en not_active Withdrawn
- 1999-11-19 WO PCT/US1999/027634 patent/WO2000030629A2/en not_active Ceased
- 1999-11-19 CN CN99815206A patent/CN1348378A/zh active Pending
- 1999-11-19 ID IDW00200101387A patent/ID29801A/id unknown
- 1999-11-19 BR BR9915636-9A patent/BR9915636A/pt not_active IP Right Cessation
- 1999-11-19 JP JP2000583512A patent/JP2003524609A/ja active Pending
2001
- 2001-05-23 NO NO20012555A patent/NO20012555L/no not_active Application Discontinuation
- 2001-05-25 ZA ZA200104310A patent/ZA200104310B/en unknown
2008
- 2008-03-06 US US12/043,845 patent/US20080214490A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU1741200A (en)	2000-06-13
CA2352262A1 (en)	2000-06-02
US20020013289A1 (en)	2002-01-31
KR20010101066A (ko)	2001-11-14
US20080214490A1 (en)	2008-09-04
US6462028B2 (en)	2002-10-08
NO20012555D0 (no)	2001-05-23
WO2000030629A3 (en)	2001-06-07
WO2000030629A2 (en)	2000-06-02
CN1348378A (zh)	2002-05-08
ZA200104310B (en)	2002-10-24
AU764452B2 (en)	2003-08-21
ID29801A (id)	2001-10-11
EP1133304A2 (en)	2001-09-19
JP2003524609A (ja)	2003-08-19
BR9915636A (pt)	2002-12-24

Legal Events

Date	Code	Title	Description
2003-07-28	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20012555L (no)	2001-07-24	Fremgangsmåte for å fremme cervikale og vaginale sekresjoner
DK1012154T3 (da)	2004-07-26	Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf
NZ333983A (en)	2000-09-29	Method of treating sinusitis with uridine triphosphates and related compounds
Hattori et al.	1996	Nucleosides and nucleotides. 158. 1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-Ethynyl-β-D-ribo-pentofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity
US6140496A (en)	2000-10-31	Precursors for deoxyribonucleotides containing non-standard nucleosides
Huang et al.	1991	Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis
Yoshimura et al.	1997	A novel synthesis of 2 ‘-modified 2 ‘-deoxy-4 ‘-thiocytidines from d-Glucose1
Martin et al.	1976	mRNA guanylyltransferase and mRNA (guanine-7-)-methyltransferase from vaccinia virions. Donor and acceptor substrate specificites.
ATE196912T1 (de)	2000-10-15	Propargylethoxyamino nucleotide
AR001045A1 (es)	1997-09-24	Procedimiento para purificar y aislar 2'-desoxi-2',2'-difluoronucleosidos enriquecidos en beta anomeros
DE60144479D1 (id)	2011-06-01
BR0114837A (pt)	2006-05-09	nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
NZ543867A (en)	2009-05-31	Modified fluorinated nucleoside analogues
BRPI0518984A2 (pt)	2008-12-16	anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal
IL93164A0 (en)	1990-11-05	Purine nucleosides and their medical use
Gudmundsson et al.	2000	Synthesis of fluorosugar analogues of 2, 5, 6-trichloro-1-(β-D-ribofuranosyl) benzimidazole as antivirals with potentially increased glycosidic bond stability
JP2004522794A (ja)	2004-07-29	Ｃ２，５’−二置換およびｎ６，ｃ２，５’−三置換アデノシン誘導体、並びにこれらの様々な使用
Moreau et al.	2012	Aberrant cyclization affords a C-6 modified cyclic adenosine 5′-diphosphoribose analogue with biological activity in Jurkat T cells
WO2001045691A3 (en)	2002-04-18	Method of treating gastrointestinal tract disease with purinergic receptor agonists
Abe et al.	1982	Role of dephosphorylation in accumulation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity
Lum et al.	2000	Human intestinal es nucleoside transporter: molecular characterization and nucleoside inhibitory profiles
KR900701279A (ko)	1990-12-01	2',5'-올리고아데닐레이트 유도체의 치료학적 사용
RU2183213C2 (ru)	2002-06-10	Модифицированные нуклеозид-5'-трифосфаты как антивирусные агенты
Azuma et al.	2001	Cellular pharmacokinetics and pharmacodynamics of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC)
Wenzel et al.	1998	Self-Complementary Oligodeoxyribonucleotides Incorporating L-Related Isodeoxynucleosides: Synthesis, Physical Characterization, Enzymology, and CD Studies